US 7,524,957 B2
Compounds effecting glucokinase
Scott Boyd, Cheshire (United Kingdom); Peter William Rodney Caulkett, Cheshire (United Kingdom); Rodney Brian Hargreaves, Cheshire (United Kingdom); Suzanne Saxon Bowker, Cheshire (United Kingdom); Roger James, Cheshire (United Kingdom); Clifford David Jones, Cheshire (United Kingdom); Darren McKerrecher, Cheshire (United Kingdom); Michael Howard Block, Waltham (United Kingdom); and Craig Johnstone, Cheshire (United Kingdom)
Assigned to AstraZeneca AB, Sodertalje (Sweden)
Filed on Feb. 01, 2008, as Appl. No. 12/24,561.
Application 12/024561 is a continuation of application No. 10/486496, granted, now 7,390,908, previously published as PCT/GB02/03745, filed on Aug. 15, 2002.
Claims priority of application No. 0102764 (SE), filed on Aug. 17, 2001.
Prior Publication US 2008/0207636 A1, Aug. 28, 2008
Int. Cl. C07D 213/02 (2006.01); C07D 231/10 (2006.01); C07D 277/20 (2006.01); C07D 285/12 (2006.01); C07D 295/00 (2006.01); A61K 31/496 (2006.01); A61K 31/426 (2006.01); A61K 31/415 (2006.01); A61K 31/433 (2006.01)
U.S. Cl. 544—405  [544/367; 544/406; 546/269.7; 548/128; 548/194; 548/364.1; 514/252.1; 514/252.12; 514/336; 514/365; 514/372; 514/403] 22 Claims
 
1. A compound of Formula (IIf) or a salt, solvate, or prodrug thereof;

OG Complex Work Unit Drawing
wherein
Het is a monocyclic heterocyclyl, and the Het and C1-6alkyl groups are independently optionally substituted with up to 3 groups selected from R4 and the C1-6alkyl group optionally contains a double bond;
each X and X1 is a linker independently selected from
—O-Z-, —O-Z-O-Z-, —C(O)O-Z-, —OC(O)-Z-, —S-Z-, —SO-Z-, —SO2-Z-, —N(R6)-Z-, —N(R6)SO2-Z-, —SO2N(R6)-Z-, —CH═CH-Z-, —C≡C-Z-, —N(R6)CO-Z-, —CON(R6)-Z-, —C(O)N(R6)S(O)2-Z-, —S(O)2N(R6)C(O)-Z-, —C(O)-Z-, -Z-, —C(O)Z-O-Z-, —N(R6)—C(O)-Z-O-Z-, —O-Z-N(R6)-Z-, and —O—C(O)-Z-O-Z-;
each Z is independently selected from a direct bond, C2-6alkenylene and a group of the formula
—(CH2)p—C(R6a)2—(CH2)q—;
each R4 is independently selected from halo, —CH3-aFa, CN, NH2, C1-6alkyl, —OC1-6alkyl, —COOH, —C(O)OC1-6alkyl, OH, phenyl optionally substituted with C1-6alkyl or —C(O)OC1-6alkyl, and R5—X1—;
R5 is selected from hydrogen, C1-6alkyl, —CH3-aFa, phenyl, naphthyl, heterocyclyl, and C3-7cycloalkyl; wherein R5 is optionally substituted with one or more substituents independently selected from halo, C1-6alkyl, —OC1-6alkyl, —CH3-aFa, CN, OH, NH2, COOH, and —C(O)OC1-6alkyl;
each Z1 is independently selected from a direct bond, C2-6alkenylene and a group of the formula —(CH2)p—C(R6a)2—(CH2)q—;
R3 is heterocyclyl, wherein the atom at the two position of the heterocyclyl ring relative to the amide group, to which R3 is attached, is an sp2 hybridised nitrogen; wherein R3 is optionally substituted with up to 2 R7 groups and wherein R3 is not pyridyl;
R6 is independently selected from hydrogen, C1-6alkyl, and —C2-4alkyl-O—C1-4alkyl;
R6a is independently selected from hydrogen, halo, C1-6alkyl, and —C2-4alkyl-O—C1-4alkyl;
each R7 is independently selected from
C1-6alkyl, C2-6alkenyl, C2-6alkynyl, (CH2)0-3aryl, (CH2)0-3heterocyclyl, (CH2)0-3C3-7cycloalkyl, OH, C1-6alkyl-OH, halo, C1-6alkyl-halo, OC1-6alkyl, (CH2)0-3S(O)0-2R8, SH, SO3H, thioxo, NH2, CN, (CH2)0-3NHSO2R8, (CH2)0-3COOH, (CH2)0-3—O—(CH2)0-3R8, (CH2)0-3C(O)(CH2)0-3R8, (CH2)0-3C(O)OR8, (CH2)0-3C(O)NH2, (CH2)0-3C(O)NH(CH2)0-3R8, (CH2)0-3NH(CH2)0-3R8, (CH2)0-3NHC(O)(CH2)0-3R8; (CH2)0-3C(O)NHSO2R8, and (CH2)0-3SO2NHC(O)—R8; wherein any alkyl chain, cycloalkyl ring or heterocyclyl ring within R7 is optionally substituted with one of more substituents independently selected from C1-4alkyl, OH, halo, CN, NH2, N—C1-4alkylamino, N,N-di-C1-4alkylamino, and OC1-4alkyl;
R8 is selected from hydrogen, C1-6alkyl, aryl, heterocyclyl, C3-7cycloalkyl, OH, C1-6alkyl-OH, COOH, C(O)OC1-6alkyl, N(R6)C1-6alkyl, OC1-6alkyl, C0-6alkylOC(O)C1-6alkyl, and C(OH)(C1-6alkyl)C1-6alkyl; wherein an alkyl chain or aryl, heterocyclyl or cycloalkyl ring within R8 is optionally substituted with one of more substituents independently selected from C1-4alkyl, OH, halo, CN, NH2, —NH—C1-4alkyl, —N-di-(C1-4alkyl) and OC1-4alkyl;
each a is independently 1, 2, or 3;
p is independently 0, 1, 2, or 3;
q is independently 0, 1, 2, or 3;
and p+q<4;
provided that:
(i) an unbranched, unsubstituted alkyl chain cannot exceed C6alkyl in length;
(ii) only one X group can be —NHC(O)—; and
(iii) when X is independently selected from —C(O)NH—, —NHC(O)—, —O—, —S(O2)NH—, and a direct bond wherein one X group is —NHC(O)—, Het-Z1 is selected from 4,5-dihydro-5-oxo-pyrazolyl, thienyl, or pyridyl and Het-Z1 is optionally substituted with R4, then R3 cannot be unsubstituted thiazole, 4,5-dihydro-5-oxo-pyrazolyl substituted with trichlorophenyl, 4,5,6,7-tetrahydro-benzo[b]thiophene substituted with ethoxycarbonyl or pyridyl optionally independently mono or di-substituted with methyl, ethoxy, or propylcarbonylamino.